Bayer
FDA Approves Nubeqa to Treat Prostate Cancer
Bayer's Nubeqa was approved for the treatment of patients with nonmetastatic castration-resistant prostate ...
AUGUST 5, 2019
FDA Approves Vitrakvi for Solid Tumors With NTRK Gene Fusions
Larotrectinib is indicated for tumors that have a NTRK gene fusion without a known acquired resistance mutation, ...
NOVEMBER 30, 2018
FDA Approves HCC Indication for Lenvima
The FDA approved a new indication for Lenvima for first-line treatment of patients with unresectable hepatocellular ...
AUGUST 20, 2018
Load more